Speaker illustration

Mr Madan Raj Poudel

University Clinic OWL, Bielefeld (Germany)

Member of:

European Society of Cardiology

Spectacular and unexpected a rare case of a giant thrombosed left ventricular aneurysm after silent myocardial infarction - challenging differential diagnosis of true or false aneurysms

Event: ESC Congress 2024

Topic: Echocardiography

Session: Rare causes of heart failure

Thumbnail

ST-elevation myocardial infarction with unexpected ventricular septal defect, covered rupture & pericardial tamponade managed by combined percutaneous circulatory support as bridge to surgical repair

Event: ESC Congress 2024

Topic: Clinical

Session: Mechanical circulatory support

Thumbnail

Extremely elevated lipoprotein (a) as an independent risk factor for peripheral arterial disease in large patient cohort

Event: ESC Congress 2020

Topic: Peripheral Artery Disease

Session: Peripheral Vascular and Cerebrovascular Disease ePosters

Thumbnail

Extremely elevated lipoprotein (a) as an independent risk factor for coronary heart disease in large patient cohort

Event: ESC Congress 2019

Topic: Prevention

Session: Long term prognosis in coronary artery disease

Thumbnail

Real world prospective one year monocentric follow up study investigating novel lipid lowering agents class proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab

Event: EuroPrevent 2019

Topic: Lipids

Session: Risk Factors and Prevention - Lipids

Thumbnail

Aortic valve stenosis in patients with extremely elevated lipoprotein(a) levels

Event: ESC Congress 2018

Topic: Clinical, Other

Session: Aortic disease: clinical

Thumbnail

First real world experience with the novel lipid-lowering drug PCSK9 inhibitor evolocumab in patients undergoing lipid apheresis: 1-year follow up

Event: EuroPrevent 2018

Topic: Lipids

Session: Moderated Poster Session II

Thumbnail

Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab /alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis

Event: EuroPrevent 2018

Topic: Lipids

Session: Lipids

Thumbnail

Efficacy of the PCSK9 inhibitors evolocumab/alirozumab in the reduction of LDL and Lp (a) in patients with familial hypercholesterolemia/manifest atherosclerosis in a real world setting

Event: EuroPrevent 2018

Topic: Lipids

Session: Lipids

Thumbnail

Reduction of LDL and Lp (a) under the PCSK9 inhibitor Evolocumab/Alirozumab in patients with familial hypercholesterolemia or manifest atherosclerosis

Event: EuroPrevent 2017

Topic: Lipids

Session: Diabetes/ Lipids/Obesity/Nutrition_Part 2

Thumbnail